Influenza viral load and peramivir kinetics after single administration and proposal of regimens for peramivir administration against resistant variants

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 3, 2015, Pages 1643-1649

  Sato, Masatoki ^a   Ito, Masaki ^b   Suzuki, Shigeo ^c   Sakuma, Hiroko ^d   Takeyama, Aya ^b   Oda, Shinichi ^e   Watanabe, Masahiro ^f   Hashimoto, Koichi ^a   Miyazaki, Kyohei ^a   Kawasaki, Yukihiko ^a   Hosoya, Mitsuaki ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b Soma General Hospital   (Japan)

^c Ohara General Hospital   (Japan)

^d HOSHI GENERAL HOSPITAL   (Japan)

^e Iwase Hospital   (Japan)

^f Department of Pediatrics South Aizu Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PERAMIVIR; VIRUS RNA; ANTIVIRUS AGENT; CYCLOPENTANE DERIVATIVE; ENZYME INHIBITOR; GUANIDINE DERIVATIVE; SIALIDASE; VIRUS PROTEIN;

ADOLESCENT; ANTIVIRAL SUSCEPTIBILITY; AREA UNDER THE CURVE; ARTICLE; ASPIRATION; BODY WEIGHT; CHILD; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; INFANT; INFLUENZA A; INFLUENZA B; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NOSE SMEAR; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SERUM; SINGLE DRUG DOSE; UPPER RESPIRATORY TRACT; VIRUS ISOLATION; VIRUS LOAD; ANTAGONISTS AND INHIBITORS; ANTIVIRAL RESISTANCE; DRUG EFFECTS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA, HUMAN; KINETICS; METABOLISM; PRESCHOOL CHILD;

ADOLESCENT; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CYCLOPENTANES; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; FEMALE; GUANIDINES; HUMANS; INFANT; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA, HUMAN; KINETICS; MALE; NEURAMINIDASE; VIRAL LOAD; VIRAL PROTEINS;

EID: 84923255568     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04263-14     Document Type: Article

References (25)

1. Neuzil KM, Mellen BG, Wright PF, Mitchel EF, Jr, Griffin MR. 2000. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med 342:225-231. http://dx.doi.org/10.1056/NEJM200001273420401.
2. Katayose M, Hosoya M, Haneda T, Yamaguchi H, Kawasaki Y, Sato M, Wright PF. 2011. The effectiveness of trivalent inactivated influenza vaccine in children over six consecutive influenza seasons. Vaccine 29:1844-1849. http://dx.doi.org/10.1016/j.vaccine.2010.12.049.
3. Sugaya N, Kohno S, Ishibashi T, Wajima T, Takahashi T. 2012. Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection. Antimicrob Agents Chemother 56:369-377. http://dx.doi.org/10.1128/AAC.00132-11.
4. Kohno S, Yen MY, Cheong HJ, Hirotsu N, Ishida T, Kadota J, Mizuguchi M, Kida H, Shimada J, S-021812 Clinical Study Group. 2011. Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. Antimicrob Agents Chemother 55:5267-5276. http://dx.doi.org/10.1128/AAC.00360-11.
5. Storms AD, Gubareva LV, Su S, Wheeling JT, Okomo-Adhiambo M, Pan CY, Reisdorf E, St George K, Myers R, Wotton JT, Robinson S, Leader B, Thompson M, Shannon M, Klimov A, Fry AM, US Antiviral Resistance Surveillance Working Group. 2012. Oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United States, 2010-11. Emerg Infect Dis 18:308-311. http://dx.doi.org/10.3201/eid1802.111466.
6. Okomo-Adhiambo M, Nguyen HT, Abd Elal A, Sleeman K, Fry AM, Gubareva LV. 2014. Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011-2012: application of the WHO antiviral working group criteria. Influenza Other Respir Viruses 8:258-265. http://dx.doi.org/10.1111/irv.12215.
7. Takashita E, Ejima M, Itoh R, Miura M, Ohnishi A, Nishimura H, Odagiri T, Tashiro M. 2014. A community cluster of influenza A (H1N1) pdm09 virus exhibiting cross-resistance to oseltamivir and peramivir in Japan, November to December 2013. Euro Surveill. 19(1):pii=20666. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20666.
8. Whitley RJ, Boucher CA, Lina B, Nguyen-Van-Tam JS, Osterhaus A, Schutten M, Monto AS. 2013. Global assessment of resistance to neuraminidase inhibitors, 2008-2011: the Influenza Resistance Information Study (IRIS). Clin Infect Dis 56:1197-1205. http://dx.doi.org/10.1093/cid/cis1220.
9. Bautista E, Chotpitayasunondh T, Gao Z, Harper SA, Shaw M, Uyeki TM, Zaki SR, Hayden FG, Hui DS, Kettner JD, Kumar A, Lim M, Shindo N, Penn C, Nicholson KG. 2010. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 362:1708-1719. http://dx.doi.org/10.1056/NEJMra1000449.
10. Gao HN, Lu HZ, Cao B, Du B, Shang H, Gan JH, Lu SH, Yang YD, Fang Q, Shen YZ, Xi XM, Gu Q, Zhou XM, Qu HP, Yan Z, Li FM, Zhao W, Gao ZC, Wang GF, Ruan LX, Wang WH, Ye J, Cao HF, Li XW, Zhang WH, Fang XC, He J, Liang WF, Xie J, Zeng M, Wu XZ, Li J, Xia Q, Jin ZC, Chen Q, Tang C, Zhang ZY, Hou BM, Feng ZX, Sheng JF, Zhong NS, Li LJ. 2013. Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med 368:2277-2285. http://dx.doi.org/10.1056/NEJMoa1305584.
11. Sleeman K, Guo Z, Barnes J, Shaw M, Stevens J, Gubareva LV. 2013. R292K substitution and drug susceptibility of influenza A(H7N9) viruses. Emerg Infect Dis 19:1521-1524. http://dx.doi.org/10.3201/eid1909.130724.
12. Ward CL, Dempsey MH, Ring CJ, Kempson RE, Zhang L, Gor D, Snowden BW, Tisdale M. 2004. Design and performance testing of quantitative real time PCR assays for influenza A and B viral load measurement. J Clin Virol 29:179-188. http://dx.doi.org/10.1016/S1386-6532(03)00122-7.
13. Wenzel JJ, Panning M, Kaul KL, Mangold KA, Revell PA, Luna RA, Zepeda H, Perea L, Vazquez-Perez JA, Young S, Rodic-Polic B, Eickmann M, Drosten C, Jilg W, Reischl U. 2010. Analytical performance determination and clinical validation of the novel Roche Real-Time Ready Influenza A/H1N1 Detection Set. J Clin Microbiol 48: 3088-3094. http://dx.doi.org/10.1128/JCM.00785-10.
14. National Institute of Infectious Diseases. 2014. Manual to detect influenza virus. (In Japanese.) National Institute of Infectious Diseases, Tokyo, Japan. http://www.nih.go.jp/niid/images/lab-manual/Influenza2014.pdf.
15. Sato M, Honzumi K, Sato T, Hashimoto K, Watanabe M, Miyazaki K, Kawasaki Y, Hosoya M. 2014. Sequential influenza B viral load and susceptibility in children treated with oseltamivir and zanamivir. Pediatr Infect Dis J 33:e168-e172. http://dx.doi.org/10.1097/INF.00000000000 00266.
16. Rennard SI, Basset G, Lecossier D, O'Donnell KM, Pinkston P, Martin PG, Crystal RG. 1986. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol 60: 532-538.
17. Kaulbach HC, White MV, Igarashi Y, Hahn BK, Kaliner MA. 1993. Estimation of nasal epithelial lining fluid using urea as a marker. J Allergy Clin Immunol 92:457-465. http://dx.doi.org/10.1016/0091-6749(93)90125-Y.
18. Pharmaceuticals and Medical Devices Agency. 2014. Interview form of peramivir. (In Japanese.) Pharmaceuticals and Medical Devices Agency, Tokyo, Japan. http://www.info.pmda.go.jp/go/pack/6250405A1032-1-02/.
19. Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R, Ipe D, Mills RG, Ward P. 2001. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 20:127-133. http://dx.doi.org/10.1097/00006454-200102000-00002.
20. Hedrick JA, Barzilai A, Behre U, Henderson FW, Hammond J, Reilly L, Keene O. 2000. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr Infect Dis J 19:410-417. http://dx.doi.org/10.1097/00006454-200005000-00005.
21. Sato M, Hosoya M, Kato K, Suzuki H. 2005. Viral shedding in children with influenza virus infections treated with neuraminidase inhibitors. Pediatr Infect Dis J 24:931-932. http://dx.doi.org/10.1097/01.inf.000 0180976.81055.ce.
22. Smith BJ, McKimm-Breshkin JL, McDonald M, Fernley RT, Varghese JN, Colman PM. 2002. Structural studies of the resistance of influenza virus neuraminidase to inhibitors. J Med Chem 45:2207-2212. http://dx.doi.org/10.1021/jm010528u.
23. Drusano GL, Preston SL, Smee D, Bush K, Bailey K, Sidwell RW. 2001. Pharmacodynamic evaluation of RWJ-270201, a novel neuraminidase inhibitor, in a lethal murine model of influenza predicts efficacy for oncedaily dosing. Antimicrob Agents Chemother 45:2115-2118. http://dx.doi.org/10.1128/AAC.45.7.2115-2118.2001.
24. Brown AN, Bulitta JB, McSharry JJ, Weng Q, Adams JR, Kulawy R, Drusano GL. 2011. Effect of half-life on the pharmacodynamic index of zanamivir against influenza virus delineated by a mathematical model. Antimicrob Agents Chemother 55:1747-1753. http://dx.doi.org/10.1128/AAC.01629-10.
25. Renaud C, Pergam SA, Polyak C, Jain R, Kuypers J, Englund JA, Corey L, Boeckh MJ. 2010. Early emergence of an H275Y mutation in a hematopoietic cell transplant recipient treated with intravenous peramivir. Transpl Infect Dis 12: 513-517. http://dx.doi.org/10.1111/j.1399-3062.2010.00582.x.